Sonablate Corp., a global leader in non-invasive focused ultrasound technologies, in partnership with CanAm scientific, announces exclusive agreement with CMC Hospital in Dubai. This achievement marks a significant milestone, as CMC Hospital Dubai becomes the pioneering healthcare facility in the GCC territory to provide Sonablate HIFU as a cutting-edge treatment option for prostate diseases.
“CanAm Scientific strongly believes that this technology will change the lives of thousands upon thousands of men in the GCC. The preservation of a man’s quality of life and the minimally invasive approach of the Sonablate HIFU perfectly align with the type of legacy CanAm Scientific wants to create in the region,” said Anthony Travonti, CEO of CanAm Scientific.“Our strategic partnership with CMC, alongside the extensive expertise of local partner Albwardy Investment Group, underscores our commitment to mutual growth, innovation and collaboration between nations, pioneering the advancement of health care technologies,” added Travonti.
"We are excited to partner with CanAm Scientific to introduce the groundbreaking HIFU technology to CMC Hospital Dubai, bringing the latest advancements in prostate disease treatment to this region,” said Mr. Abdulrahman Abdulaziz Khansaheb, Chairman of CMC Hospital Dubai.
“Sonablate Robotic HIFU is proud to be partnering with a globally recognized institution like CMC Hospital Dubai to bring this industry leading focal therapy to the Urologic community in the U.A.E. The highly skilled Urology team at CMC, headed up by market leading surgeon Dr. Madi, will once again bring innovative and life improving technologies to Dubai and the entire GCC region,” said Alex Gonzalez, Chief Commercial Officer of Sonablate Corp. “Image guided focal therapy is one of the hottest topics in urology and we have seen a significant amount of interest from patients demanding access to this quality of life preserving technology” added Gonzalez.
_____________________________________________________________________________________
About Sonablate Corp.
Sonablate Corp. is a world leader in non-invasive focused ultrasound technologies. Sonablate Corp. is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. Sonablate Corp., with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the Sonablate®, which has 510(K) clearance in the U.S and NMPA clearance in China; and Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 50 countries outside the U.S. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. For additional information, visit www.sonablate.com.
About CanAm Scientific:
CanAm Scientific/ CanAm Medical is a global leader in the technology, supply and manufacturing industries, committed to serving the evolving needs of the international community. Led by an experienced management team and with deep partnerships in the Middle East, CanAm Scientific/CanAm Medical boasts consistent focus on manufacturing and providing innovative products, and superior service amongst its diverse portfolio, which includes surface disinfectants, fire prevention coatings, medical instrumentation, in addition to many more leading-edge technologies.
About Clemenceau Medical Center Hospital in Dubai:
Clemenceau Medical Center Hospital in Dubai is a new generation of cutting-edge hospitals anchored in Dubai Healthcare City – Phase II and part of Clemenceau Medicine International (CMI), an award-winning network of state of-the-art hospitals and medical centers in the Middle East. The hospital builds on technological advancements, innovative treatments and superior medical expertise across a wide range of specialties to deliver patient-first healthcare excellence and elevate industry standards locally, regionally and globally.
Sonablate® HIFU is approved in more than 50 countries worldwide and was the first focused ultrasound device to be FDA-cleared in the U.S. for the ablation of prostate tissue. This innovative solution for prostate diseases has allowed Sonablate® HIFU to become the industry leader in focal therapy. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
Sonablate is a registered trademark of Sonablate Corp. © 2024 Sonablate Corp. All rights reserved.
